Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

8.610 -0.040 (-0.46%)
Streaming Delayed Price Updated: 1:02 PM EDT, Aug 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,296
Open 8.590
Bid (Size) 8.570 (1)
Ask (Size) 8.620 (1)
Prev. Close 8.650
Today's Range 8.590 - 8.750
52wk Range 4.090 - 13.43
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enanta Pharmaceuticals to Participate in September Investor Conferences
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+54.0%
+54.0%
1 Month
+7.2%
+7.2%
3 Month
+47.9%
+47.9%
6 Month
+1.4%
+1.4%
1 Year
-35.3%
-35.3%

More News

Read More
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
The Analyst Verdict: Enanta Pharma In The Eyes Of 4 Experts
Via Benzinga
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series
From Enanta Pharmaceuticals, Inc.
Via Business Wire
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
Via Benzinga
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
4 Analysts Assess Enanta Pharma: What You Need To Know
Via Benzinga
Enanta Pharma Earnings Analysis: Q4 Recap
Via Benzinga
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Thursday's session: gap up and gap down stocks
Via Chartmill
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday
Via Benzinga
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 8.610
When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 08/27/25 01:02 PM ET
What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 181.29M
How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
Enanta Pharmaceuticals, Inc. - Common Stock has 181M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.